Regulatory properties of statins and rho gtpases prenylation inhibitiors to stimulate melanoma immunogenicity and promote anti-melanoma immune response

Survival of patients with advanced metastatic melanoma: The impact of novel therapies

(2016) Selma Ugurel et al.   EUROPEAN JOURNAL OF CANCER

Enhancing T cell therapy by overcoming the immunosuppressive tumor microenvironment

(2016) Ainhoa Arina et al.   SEMINARS IN IMMUNOLOGY

Natural Killer Cell Recognition of Melanoma: New Clues for a More Effective Immunotherapy

(2016) Raquel Tarazona et al.   Frontiers in Immunology

Melanoma Expressed-CD70 Is Regulated by RhoA and MAPK Pathways without Affecting Vemurafenib Treatment Activity

(2016) Christine Pich et al.   PLoS One

Melanoma-expressed CD70 is involved in invasion and metastasis

(2015) Christine Pich et al.   BRITISH JOURNAL OF CANCER

Statin use and risk of pancreatic cancer: Results from a large, clinic-based case-control study

(2015) Evan J. Walker et al.   CANCER

RAC1 P29S regulates PD-L1 expression in melanoma

(2015) Ha Linh Vu et al.   Pigment Cell & Melanoma Research

In vivo Effects in Melanoma of ROCK Inhibition-Induced FasL Overexpression

(2015) Iotefa Teiti et al.   Frontiers in Oncology

Targeting the PD-1 pathway: a promising future for the treatment of melanoma

(2014) Andrew Mamalis et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH

Statin use and risk of hepatocellular carcinoma in a U.S. population

(2014) Katherine A. McGlynn et al.   Cancer Epidemiology

A Single-Arm, Open-Label, Expanded Access Study of Vemurafenib in Patients With Metastatic Melanoma in the United States

(2014) Lawrence Flaherty et al.   CANCER JOURNAL

Mitogen-activated Protein Kinase (MAPK) Hyperactivation and Enhanced NRAS Expression Drive Acquired Vemurafenib Resistance in V600E BRAF Melanoma Cells

(2014) Michael Lidsky et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

(2014) Chong Sun et al.   NATURE

eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies

(2014) Lise Boussemart et al.   NATURE

Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease

(2014) Behzad Yeganeh et al.   PHARMACOLOGY & THERAPEUTICS

Adaptive resistance to RAF inhibitors in melanoma

(2014) Curtis H. Kugel et al.   Pigment Cell & Melanoma Research

Statins: protectors or pretenders in prostate cancer?

(2014) Hyeongsun Moon et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Statin use and risk of liver cancer: an update meta-analysis

(2014) M. Shi et al.   BMJ Open

Narrative Review: BRAF Opens the Door for Therapeutic Advances in Melanoma

(2013) Keith T. Flaherty   ANNALS OF INTERNAL MEDICINE

Design and synthesis of tag-free photoprobes for the identification of the molecular target for CCG-1423, a novel inhibitor of the Rho/MKL1/SRF signaling pathway

(2013) Jessica L Bell et al.   Beilstein Journal of Organic Chemistry

In vitro and in vivo effects of geranylgeranyltransferase I inhibitor P61A6 on non-small cell lung cancer cells

(2013) Drazen B Zimonjic et al.   BMC CANCER

BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma

(2013) D. T. Frederick et al.   CLINICAL CANCER RESEARCH

Treatment of BRAF-Mutant Melanoma: The Role of Vemurafenib and Other Therapies

(2013) S Jang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Statins are associated with reduced risk of gastric cancer: A meta-analysis

(2013) Xiao-Dan Wu et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

RAC1P29S is a spontaneously activating cancer-associated GTPase

(2013) M. J. Davis et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Statins Reduce Melanoma Development and Metastasis through MICA Overexpression

(2013) Christine Pich et al.   Frontiers in Immunology

Vemurafenib enhances MHC induction inBRAFV600Ehomozygous melanoma cells

(2013) Bishu Sapkota et al.   OncoImmunology

BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes

(2013) Zachary A Cooper et al.   OncoImmunology

Rho GTPase regulation by miRNAs and covalent modifications

(2012) Ming Liu et al.   TRENDS IN CELL BIOLOGY

Driver Mutations in Melanoma: Lessons Learned From Bench-to-Bedside Studies

(2012) Janice M. Mehnert et al.   Current Oncology Reports

Interplay between statins and PPARs in improving cardiovascular outcomes: a double-edged sword?

(2011) Pitchai Balakumar et al.   BRITISH JOURNAL OF PHARMACOLOGY

Long-term Use of Cholesterol-Lowering Drugs and Cancer Incidence in a Large United States Cohort

(2011) E. J. Jacobs et al.   CANCER RESEARCH

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion

(2011) R. D. Schreiber et al.   SCIENCE

Incidence Estimate of Nonmelanoma Skin Cancer in the United States, 2006

(2010) Howard W. Rogers et al.   ARCHIVES OF DERMATOLOGY

BRAF as therapeutic target in melanoma

(2010) Claudia Wellbrock et al.   BIOCHEMICAL PHARMACOLOGY

Direct modifications of Rho proteins: deconstructing GTPase regulation

(2010) Orane Visvikis et al.   BIOLOGY OF THE CELL

Insights into the molecular regulation of FasL (CD178) biology

(2010) Marcus Lettau et al.   EUROPEAN JOURNAL OF CELL BIOLOGY

Statin use and cancer risk: a comprehensive review

(2010) Denise M Boudreau et al.   Expert Opinion On Drug Safety

Novel role of regulatory T cells in limiting early neutrophil responses in skin

(2010) Hannah Richards et al.   IMMUNOLOGY

Melanoma Cells Treated with GGTI and IFN-γ Allow Murine Vaccination and Enhance Cytotoxic Response against Human Melanoma Cells

(2010) Guillaume Sarrabayrouse et al.   PLoS One

Design, synthesis and prostate cancer cell-based studies of analogs of the Rho/MKL1 transcriptional pathway inhibitor, CCG-1423

(2009) Chris R. Evelyn et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older

(2009) J.-L. Harousseau et al.   BLOOD

Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion

(2009) Shuh Narumiya et al.   CANCER AND METASTASIS REVIEWS

Inhibition of RhoA or Rac1? Mechanism of Cholesterol-Independent Beneficial Effects of Statins

(2009) Yoshiyuki Rikitake et al.   CIRCULATION JOURNAL

Treatment for metastatic malignant melanoma: Old drugs and new strategies

(2009) Roger Mouawad et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

The MAPK pathway in melanoma

(2009) Leslie A Fecher et al.   CURRENT OPINION IN ONCOLOGY

Yin-Yang of costimulation: crucial controls of immune tolerance and function

(2009) Roza I. Nurieva et al.   IMMUNOLOGICAL REVIEWS

An integrated view of the regulation of NKG2D ligands

(2009) Noam Stern-Ginossar et al.   IMMUNOLOGY

In vivo antitumor effect of a novel inhibitor of protein geranylgeranyltransferase-I

(2009) J. Lu et al.   MOLECULAR CANCER THERAPEUTICS

Applications for ROCK kinase inhibition

(2008) Michael F Olson   CURRENT OPINION IN CELL BIOLOGY

Rho GTPases in cancer cell biology

(2008) Francisco M. Vega et al.   FEBS LETTERS

Up on the tightrope: natural killer cell activation and inhibition

(2008) Lewis L Lanier   NATURE IMMUNOLOGY

Safety and Efficacy of Fasudil Monotherapy and Fasudil-Ozagrel Combination Therapy in Patients With Subarachnoid Hemorrhage: Sub-analysis of the Post-marketing Surveillance Study

(2008) Yoshio SUZUKI et al.   NEUROLOGIA MEDICO-CHIRURGICA

Oncogenic BRAF Regulates Melanoma Proliferation through the Lineage Specific Factor MITF

(2008) Claudia Wellbrock et al.   PLoS One

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

(2008) J. Tsai et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA